Ondansetron B. Braun

Ondansetron, the active ingredient in Ondansetron B. Braun, is a 5-HT3 receptor antagonist presented as an injectable solution for intravenous use. It prevents and treats nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative settings.

GNH USA supplies Ondansetron B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron acts on serotonin‑mediated pathways that trigger emesis, providing anti‑emetic control in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: prevents and reduces episodes during and after cancer treatment. - Postoperative nausea and vomiting: lowers incidence of nausea following surgical procedures. - Radiotherapy‑induced nausea and vomiting: helps control symptoms during radiation therapy.

Common Side Effects: - Headache: mild to moderate pain in the head. - Constipation: reduced bowel movements or hard stools. - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or weak. - Injection‑site reactions: redness, pain or swelling at the IV site. - Diarrhoea: loose, watery stools.

Serious or Rare Side Effects: - QT interval prolongation: potential cardiac rhythm disturbance. - Severe allergic reaction (anaphylaxis): difficulty breathing, swelling, rash. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity when combined with other serotonergic agents. - Cardiac arrhythmia: irregular heartbeats that may require medical attention.

Before using Ondansetron, consider the following safety measures.

- Cardiac assessment: evaluate QT interval and monitor ECG in patients with known cardiac disease. - Concomitant serotonergic drugs: avoid or closely monitor to reduce risk of serotonin syndrome. - Hepatic impairment: adjust dosing or monitor closely in patients with liver dysfunction. - Pregnancy: limited data; use only if potential benefit outweighs risk. - Allergic reactions: discontinue if signs of hypersensitivity appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ondansetron may interact with other medicines; review patient medication lists.

Major Interactions (Avoid): - QT‑prolonging agents (e.g., quinidine, amiodarone): increase risk of cardiac arrhythmia. - Other 5‑HT3 antagonists: additive anti‑emetic effect may cause excessive serotonin blockade. - Apomorphine: can cause severe hypotension and loss of consciousness.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Serotonergic agents (e.g., SSRIs, MAO inhibitors): monitor for serotonin syndrome.